This program was made possible with support from Novartis Pharmaceuticals. Video content above is prompted by the following questions: What are some of the most common concerns or questions newly ...
Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback